ClinicalTrials.gov Identifier: NCT02420756
The IDEAS Study is an observational, open-label, longitudinal cohort study designed to assess the impact of amyloid PET on patient-oriented outcomes in Medicare beneficiaries with mild cognitive impairment (MCI) or dementia of uncertain etiology. Subjects will have an amyloid PET scan and follow-up with their referring doctor as part of ongoing medical care; claims submitted to Medicare to cover a subject’s health care will be collected for up to three years.
Who may be eligible to participate?
Subjects must be 65 years of age or older and a Medicare beneficiary with a diagnosis of MCI or dementia. Subjects must have had a head MRI and/or CT scan within 24 months prior to enrollment.
Investigators: Reza Tabibi, MD, MBA and Pinky Agarwal, MD, FAAN
For More Information: Jana Akture 425.899.5393 CAkture@evergreenhealth.com